SAN FRANCISCO, Jan. 17, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced the first scientific presentation of results from the Phase 1b portion of its ongoing ALPINE ( Antibody therapy in first- Line Pancreatic cancer Investigating anti- Notch Efficacy and safety) Phase 1b/2 clinical study of OMP-59R5 (anti-Notch 2/3) in patients with advanced pancreatic cancer. OMP-59R5 is part of OncoMed's collaboration with GlaxoSmithKline (GSK). These data were presented in a poster by Eileen M. O'Reilly, M.D., of Memorial Sloan-Kettering Cancer Center at the 2014 Gastrointestinal Cancers Symposium being held in San Francisco, California.
OncoMed Pharmaceuticals Presents Data From The Phase 1b Portion Of The ALPINE Clinical Study Of OMP-59R5 In Pancreatic Cancer At The 2014 Gastrointestinal Cancers Symposium
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.